Arbeitsgemeinschaft
für angewandte
Humanpharmakologie e.V

Association for
Applied Human
Pharmacology

  

> Annual Meeting > Annual Meetings - Overview > Annual Meeting 2005 > Presentations 2005 

Presentations Annual Meeting 2005

 

Session I: Why do we need Phase I studies?

W. Seifert, Berlin

pdf
Is Phase I useful?Is-Phase-I-useful-Seifert.pdf (415 kB)

H. Fuder, Mulhouse

pdf
Healthy volunteers or patients as target population in Phase I trials?Healthy-volunteers-or-patients-Fuder.pdf (4 MB)

H. Caplain, Paris

pdf
When to stop dose escalation - MTD or MLD or ?Stop-dose-escalation-Caplain.pdf (1 MB)

 

Session II: Implications of the new EU-Directive on clinical trials

A. Patat, Paris

pdf
FranceEU-Directive-France-Patat.pdf (210 kB)

R. Frey, Wuppertal

pdf
GermanyEU-Directive-Germany-Frey.pdf (239 kB)

S. Warrington, London

pdf
United KingdomEU-Directive-UK-Warrington.pdf (442 kB)

J. van Gerven, Leiden

pdf
The NetherlandsEU-Directive-Netherlands-van-Gerven.pdf (887 kB)

C. Reh, Berlin

pdf
Central EuropeEU-Directive-Central-Europe-Reh.pdf (309 kB)

A. Patat, Paris

pdf
Comparison between European countriesComparisons-between-European-countries-Patat.pdf (438 kB)

 

Session III: Safety issues in Phase I studies

M. Sibille, Lyon

pdf
Is Phase I safe?Is-Phase-I-safe-Sibille.pdf (228 kB)

B. Reigner, Basel

pdf
First dose and dose escalationFirst-dose-and-escalation-Reigner.pdf (121 kB)

G. Sanderink, Paris

Allometric scaling
No presentation available

 

Session IV: New tools in early drug development

E. Fuseau, Aix-en-Provence

pdf
When and how does PK/PD modelling and simulation make sense in early developmentPKPD-in-early-development-Fuseau.pdf (478 kB)

K.L. Rost, Berlin

Informed consent process in pharmacogenomic studies (Germany, France, international view)
No presentation available

R. Myers, London

pdf
Imaging in early drug developmentPET-scan-Myers.pdf (4 MB)

B. Acres, Strasbourg

New compounds derived from research on proteomics
No presentation available

 

Workshops

H. Allain, Rennes

pdf
Pharmacogenomics and drug safetyPharmacogenomics-and-drug-safety-Allain.pdf (385 kB)

P. Maisonblanche, Paris

pdf
QTc: Predictability, Science, RegulationQTc-Maisonblanche.pdf (3 MB)

M. Buyse, Bruxelles

pdf
Phase I in OncologyPhase-I-in-oncology-Buyse.pdf (878 kB)

Page updated: 14-05-2009